Targeted pathological collagen delivery of sustained-release rapamycin to prevent heterotopic ossification.

Abstract

Heterotopic ossification (HO) in connective tissues like tendons and ligaments severely damages tissue structure. The pathogenesis of HO remains unclear but may involve mTOR. The results presented here indicate that tendon stem/progenitor cells do not undergo osteochondrogenic differentiation when mTOR signaling is inactivated by gene knockout or rapamycin (RAPA) treatment. Meanwhile, it is necessary to deliver RAPA to the injured sites and avoid disturbing the normal tendon. A RAPA delivery system, developed using collagen hybrid peptide (CHP) to modify the surface of poly(lactic-co-glycolic acid) (PLGA) nanoparticles, targeted RAPA specifically to pathological tendon collagen. The CHP-PLGA-RAPA nanoparticles showed excellent pathological collagen affinity, sustained-release ability, and bioactivity. In a mouse model of tendon HO, CHP-PLGA-RAPA nanoparticles specifically bound to pathological tendon and strongly suppressed HO progression. The mTOR signaling pathway appears to be a viable therapeutic target for tendon HO, and CHP-PLGA nanoparticles may be valuable for the treatment of tendon-related diseases.

• Authors: Yangwu Chen, Weiliang Shen, Chenqi Tang, Jiayun Huang, Chunmei Fan, Zi Yin, Yejun Hu, Weishan Chen, Hongwei Ouyang, Yiting Zhou, Zhengwei Mao, Xiao Chen
• Journal: Science advances (Sci Adv) Vol. 6 Issue 18 Pg. eaay9526 (05 2020) ISSN: 2375-2548 [Electronic] United States
• PMID: 32494667 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Chemical References

• Delayed-Action Preparations
• Collagen
• TOR Serine-Threonine Kinases
• Sirolimus

Topics

• Animals
• Collagen
• Delayed-Action Preparations (pharmacology)
• Mice
• Ossification, Heterotopic (drug therapy, prevention & control)
• Sirolimus (pharmacology)
• TOR Serine-Threonine Kinases (metabolism)